In vitro transcorneal diffusion of the antimicrobial macrolides azithromycin and clarithromycin and the impact on microbial keratitis

Cornea

Volumn 28, Issue 4, 2009, Pages 441-446

  Van Eyk, Armorel D ^a   Seifart, Heiner I ^a   Meyer, David ^b   Van Der Bijl, Pieter ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

Author keywords

Azithromycin; Clarithromycin; Cornea; In vitro diffusion; Permeability

Indexed keywords

AZITHROMYCIN; CARBOMER; CLARITHROMYCIN; PHOSPHATE BUFFERED SALINE; POLYACRYLIC ACID;

ANTIMICROBIAL ACTIVITY; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG CONCENTRATION; DRUG PENETRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KERATITIS; LIQUID CHROMATOGRAPHY; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; TANDEM MASS SPECTROMETRY;

ADULT; AGED; ANIMALS; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CLARITHROMYCIN; CORNEA; CORNEAL ULCER; DIFFUSION; EYE INFECTIONS, BACTERIAL; HUMANS; MIDDLE AGED; PERMEABILITY; RABBITS; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 67650585880     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/ICO.0b013e31818c901f     Document Type: Article

References (32)

1. Abshire R, Cockrum P, Crider J, et al. Topical antibacterial therapy for mycobacterial keratitis: potential for surgical prophylaxis and treatment. Clin Ther. 2004;26:191-196.
2. Lee SB, Oliver KM, Strube YN, et al. Fourth-generation fluoroquinolones in the treatment of mycobacterial infectious keratitis after laser-assisted in situ keratomileusis surgery. Can J Ophthalmol. 2005;40:750-753.
3. Solomon R, Donnenfeld ED, Azar DT, et al. Infectious keratitis after laser in situ keratomileusis: results of an ASCRS survey. J Cataract Refract Surg. 2003;29:2001-2006.
4. Winthrop KL, Steinberg EB, Holmes G, et al. Epidemic and sporadic cases of nontuberculous mycobacterial keratitis associated with laser in situ keratomileusis. Am J Ophthalmol. 2003;135:223-224.
5. Hamam RN, Noureddin B, Salti HI, et al. Recalcitrant post-LASIK Mycobacterium chelonae keratitis eradicated after the use of fourth-generation fluoroquinolone. Ophthalmology. 2006;113:950-954.
6. Gelender H, Carter HL, Bowman B, et al. Mycobacterium keratitis after laser in situ keratomileusis. J Refract Surg. 2000;16:191-195.
7. Chung MS, Goldstein MH, Driebe WT Jr, et al. Mycobacterium chelonae keratitis after laser in situ keratomileusis successfully treated with medical therapy and flap removal. Am J Ophthalmol. 2000;129:382-384.
8. Chandra NS, Torres MF, Winthrop KL, et al. Cluster of Mycobacterium chelonae keratitis cases following laser in-situ keratomileusis. Am J Ophthalmol. 2001;132:819-830.
9. Giaconi J, Pham R, Ta CN. Bilateral Mycobacterium abscessus keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2002;28: 887-890.
10. Fulcher SF, Fader RC, Rosa RH Jr, et al. Delayed-onset mycobacterial keratitis after LASIK. Cornea. 2002;21:546-554.
11. Freitas D, Alvarenga L, Sampaio J, et al. An outbreak of Mycobacterium chelonae infection after LASIK. Ophthalmology. 2003;110:276-285.
12. Rodriguez B, Holzinger KA, Le LH, et al. Mycobacterium chelonae keratitis after laser-assisted subepithelial keratectomy. J Cataract Refract Surg. 2006;32:1059-1061.
13. Chung SH, Roh MI, Park MS, et al. Mycobacterium abscessus keratitis after LASIK with Intralace femtosecond laser. Ophthalmologica. 2006; 220:277-280.
14. Moshirfar M, Meyer JJ, Espandar L. Fourth-generation fluoroquinolone- resistant mycobacterial keratitis after laser in situ keratomileusis. J Cataract Refract Surg. 2007;33:1987-1981.
15. Roy S, Bowman LM, inventors. Topical treatment for prevention of ocular infections. US patent 7,056,893. InSite Vision Inc, Alameda, CA. June 6, 2006. Available at: http://www.freepatentsonline.com/7056893.html. Accessed March 19, 2008.
16. Jhanji V, Sharma N, Satpathy G, et al. Fourth-generation fluoroquinolone-resistant bacterial keratitis. J Cataract Refract Surg. 2007;33:1488-1489.
17. Moshirfar M, Mirzaian G, Feiz V, et al. Fourth-generation fluoroquinolone-resistant bacterial keratitis after refractive surgery. J Cataract Refract Surg. 2006;32:515-518.
18. Gross RH, Holland GN, Elias SJ, et al. Corneal pharmacokinetics of topical clarithromycin. Invest Ophthalmol Vis Sci. 1995;36:965-968.
19. Kuehne JJ, Yu AL, Holland GN, et al. Corneal pharmacokinetics of topically applied azithromycin and clarithromycin. Am J Ophthalmol. 2004;138:547-553.
20. Van der Bijl P, Engelbrecht AH, Van Eyk AD, et al. Comparative permeability of human and rabbit corneas to cyclosporin and tritiated water. J Ocul Pharmacol Ther. 2002;18:419-427.
21. Van der Bijl P, Van Eyk AD, Meyer D. Effects of three penetration enhancers on transcorneal permeation of cyclosporine. Cornea. 2001;20: 505-508.
22. Van der Bijl P, Van Eyk AD, Seifart HI, et al. In vitro transcorneal penetration of metronidazole and its potential use as adjunct therapy in Acanthamoeba keratitis. Cornea. 2004;23:386-389.
23. Van der Bijl P, Van Eyk AD, Seifart HI, et al. Diffusion of metronidazole released from aqueous solution and a gel through human and rabbit corneas. J Ocul Pharmacol Ther. 2004;20:421-429.
24. Van Eyk AD, Van der Bijl P, Meyer D. In vitro diffusion of the immunosuppressant tacrolimus through human and rabbit cornea. J Ocul Pharmacol Ther. 2007;23:146-151.
25. Motulsky H, ed. Intuitive biostatistics. In: GraphPad Software. New York, NY: Oxford University Press; 1995.
26. Bowman LM, Dawson CR, inventors. Topical treatment or prevention of ocular infections. May 29, 2001. US Patent Number 6239113. InSite Vision Inc, Alameda, CA. Available at: http://www.patentstorm.us/ patents/6239113- description.html. Accessed April 14, 2008.
27. Du Plessis J, Pugh WJ, Judefeind A, et al. The effect of hydrogen bonding on diffusion across model membranes: consideration of the number of H-bonding groups. Eur J Pharm Sci. 2001;13:135-141.
28. Roberts MS, Pugh WH, Hadgraft J. Epidermal permeability: penetrant structure relationships: 2. The effect of H-bonding groups in penetrants on their diffusion through the stratum corneum. Int J Pharm. 1996;132:23-32.
29. Ives TJ, Merston EL, Regnery RL, et al. In vitro susceptibilities of Rickettsia and Bartonella spp. to 14-hydroxy-clarithromycin as determined by immunofluorescent antibody analysis of infected vero cell monolayers. J Antimicrob Chemother. 2000;45:305-310.
30. Norcia LJL, Silvia AM, Santoro SL, et al. In vitro microbiological characterization of a novel azalide, two triamilides and an azalide ketal against bovine and porcine respiratory pathogens. J Antibiot. 2004;57:280-288.
31. Van Eyk AD, Van der Bijl P, Moll LM. Physicochemical characteristics of molecules and their diffusion across human vaginal mucosa. Eur J Inflam. 2008;6.
32. Teargel, liquid gel [package insert]. Adcock Ingram Ltd; Midrand, South Africa. 1989. Registration number. W/15.4/269.